The effect of selective serotonin reuptake inhibitors in healthy subjects. A systematic review

Nordic Journal of Psychiatry

Volumn 64, Issue 3, 2010, Pages 153-163

  Knorr, Ulla ^a   Kessing, Lars Vedel ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Antidepressants; Depression; Endophenotype; Healthy; Methodology; SSRI

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG TOLERABILITY; FAMILY HISTORY; HUMAN; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REVIEW; SEIZURE; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

AFFECT; ANTIDEPRESSIVE AGENTS; BIAS (EPIDEMIOLOGY); BIOLOGICAL AVAILABILITY; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PATIENT SELECTION; PERSONALITY INVENTORY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 77952125504     PISSN: 08039488     EISSN: 15024725     Source Type: Journal    
DOI: 10.3109/08039480903511381     Document Type: Review

References (61)

1. Regier DA, Kaelber CT, Rae DS, Farmer ME, Knauper B, Kessler RC, et al. Limitations of diagnostic criteria and assessment instruments for mental disorders-Implications for research and policy. Arch Gen Psychiatry 1998;55:109-15.
2. Knutson B, Wolkowitz OM, Cole SW, Chan T, Moore EA, Johnson RC, et al. Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 1998;155:373-9.
3. Christensen MV, Kyvik KO, Kessing LV. Subclinical psychopathology and socio-economic status in unaffected twins discordant for affective disorder. J Psychiatr Res 2006.
4. Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected twins discordant for affective disorder. Psychol Med 2006;36:1119-29.
5. Vinberg M, Bech P, Kyvik KO, Kessing LV. Quality of life in unaffected twins discordant for affective disorder. J Affect Disord 2007;99:133-8. (Pubitemid 46275028)
6. Vinberg M, Kyvik KO, Andersen PK, Kessing LV. Salivary cortisol in unaffected twins discordant for affective disorder. Journal of Psychiatric Research 2008 (in press).
7. Dumont GJ, de Visser SJ, Cohen AF, van Gerven JM. Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. Br J Clin Pharmacol 2005;59:495-510.
8. Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol 2005;20:533-59.
9. Ramaekers JG. Antidepressants and driver impairment: Empirical evidence from a standard on-the-road test. J Clin Psychiatry 2003;64:20-9.
10. Rijnbeek B, de Visser SJ, Franson KL, Cohen AF, van Gerven JM. REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers. J Psychopharmacol 2003;17:196-203.
11. Schmitt JA, Wingen M, Ramaekers JG, Evers EA, Riedel WJ. Serotonin and human cognitive performance. Curr Pharm Des 2006;12:2473-86.
12. Venn HR, Watson S, Gallagher P, Young AH. Facial expression perception: An objective outcome measure for treatment studies in mood disorders? Int J Neuropsychopharmacol 2006;9:229-45.
13. Volz HP, Sturm Y. Antidepressant drugs and psychomotor performance. A review. Neuropsychobiology 1995;31:146-55.
14. Wilson S, Argyropoulos S. Antidepressants and sleep: A qualitative review of the literature. Drugs 2005;65:927-47.
15. Moher D, Schulz KF, Altman D. The CONSORT Statement: Revised recommendations for improving the quality of reports of parallelgroup randomized trials 2001. Explore (NY) 2005;1:40-5.
16. Madeo B, Bettica P, Milleri S et al. The effects of citalopram and fl uoxetine on sexual behavior in healthy men: Evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebocontrolled, double-blind, double-dummy, parallel group study. J Sex Med 2008;5:2431-41.
17. Briscoe VJ, Ertl AC, Tate DB, Dawling S, Davis SN. Effects of a selective serotonin reuptake inhibitor, fl uoxetine, on counterregulatory responses to hypoglycemia in healthy individuals. Diabetes 2008;57:2453-60.
18. Paul MA, Gray G, Lange M. The impact of sertraline on psychomotor performance. Aviat Space Environ Med 2002;73:964-70.
19. Wilson SJ, Bailey JE, Alford C, Weinstein A, Nutt DJ. Effects of 5 weeks of administration of fl uoxetine and dothiepin in normal volunteers on sleep, daytime sedation, psychomotor performance and mood. J Psychopharmacol 2002;16:321-31.
20. Pohl R, Balon R, Jayaraman A, Doll RG, Yeragani V. Effect of fl uoxetine, pemoline and placebo on heart period and QT variability in normal humans. J Psychosom Res 2003;55:247-51.
21. Gerdelat-Mas A, Loubinoux I, Tombari D, Rascol O, Chollet F, Simonetta-Moreau M. Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage 2005;27:314-22.
22. Loubinoux I, Tombari D, Pariente J, Gerdelat-Mas A, Franceries X, Cassol E, et al. Modulation of behavior and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 2005;27:299-313. (Pubitemid 41074833)
23. Peran P, Demonet JF, Cardebat D. Paroxetine-induced modulation of cortical activity supporting language representations of action. Psychopharmacology (Berl) 2008;195:487-96.
24. Chial HJ, Camilleri M, Burton D, Thomforde G, Olden KW, Stephens D. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003;284:G130-7.
25. Talley NJ, Camilleri M, Chitkara DK, Bouras E, Locke GR 3rd, Burton D, et al. Effects of desipramine and escitalopram on postprandial symptoms induced by the nutrient drink test in healthy volunteers: A randomized, double-blind, placebo-controlled study. Digestion 2005;72:97-103.
26. Schmitt JA, Kruizinga MJ, Riedel WJ. Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J Psychopharmacol 2001;15:173-9.
27. Schmitt JA, Ramaekers JG, Kruizinga MJ, van Boxtel MP, Vuurman EF, Riedel WJ. Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man. J Psychopharmacol 2002;16:207-14.
28. Riedel WJ, Eikmans K, Heldens A, Schmitt JA. Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J Psychopharmacol 2005;19:12-20.
29. Murphy SE, Yiend J, Lester KJ, Cowen PJ, Harmer CJ. Short-term serotonergic but not noradrenergic antidepressant administration reduces attentional vigilance to threat in healthy volunteers. Int J Neuropsychopharmacol 2008;1-11.
30. Taylor M, Murphy SE, Selvaraj S, Wylezinkska M, Jezzard P, Cowen PJ, et al. Differential effects of citalopram and reboxetine on cortical Glx measured with proton MR spectroscopy. J Psychopharmacol 2008;22:473-6.
31. Grillon C, Chavis C, Covington MF, Pine DS. Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: A fearpotentiated startle study. Neuropsychopharmacology 2008.
32. Jezova D, Duncko R. Enhancement of stress-induced pituitary hormone release and cardiovascular activation by antidepressant treatment in healthy men. J Psychopharmacol 2002;16:235-40.
33. Ramaekers JG, Muntjewerff ND, O'Hanlon JF. A comparative study of acute and subchronic effects of dothiepin, fl uoxetine and placebo on psychomotor and actual driving performance. Br J Clin Pharmacol 1995;39:397-404.
34. Tse WS, Bond AJ. Serotonergic involvement in the psychosocial dimension of personality. J Psychopharmacol 2001;15:195-8.
35. Schmitt JA, Riedel WJ, Vuurman EF, Kruizinga M, Ramaekers JG. Modulation of the critical fl icker fusion effects of serotonin reuptake inhibitors by concomitant pupillary changes. Psychopharmacology (Berl) 2002;160:381-6.
36. Chial HJ, Camilleri M, Ferber I, Delgado-Aros S, Burton D, McKinzie S, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003;1:211-8.
37. Wingen M, Bothmer J, Langer S, Ramaekers JG. Actual driving performance and psychomotor function in healthy subjects after acute and subchronic treatment with escitalopram, mirtazapine, and placebo: A crossover trial. J Clin Psychiatry 2005;66:436-43.
38. Wingen M, Langer S, Ramaekers JG. Verbal memory performance during subchronic challenge with a selective serotonergic and a mixed action antidepressant. Hum Psychopharmacol 2006;21:473-9.
39. Parise G, Bosman MJ, Boecker DR, Barry MJ, Tarnopolsky MA. Selective serotonin reuptake inhibitors: Their effect on highintensity exercise performance. Arch Phys Med Rehabil 2001;82:867-71.
40. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 2004;161:1256-63.
41. Harmer CJ, Mackay CE, Reid CB, Cowen PJ, Goodwin GM. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006;59:816-20.
42. Paul MA, Gray GW, Love RJ, Lange M. SSRI effects on pyschomotor performance: Assessment of citalopram and escitalopram on normal subjects. Aviat Space Environ Med 2007;78:693-7.
43. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000;68:435-42.
44. Van Laar MW, Volkerts ER, Verbaten MN, Trooster S, van Megen HJ, Kenemans JL. Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory. Psychopharmacology (Berl) 2002;162:351-63.
45. Kotzailias N, Marker M, Jilma B. Early effects of paroxetine on serotonin storage, plasma levels, and urinary excretion: A randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2004;24:536-9.
46. Arce E, Simmons AN, Lovero KL, Stein MB, Paulus MP. Escitalopram effects on insula and amygdala BOLD activation during emotional processing. Psychopharmacology (Berl) 2007.
47. Robbe HW, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur Neuropsychopharmacol 1995;5:35-42.
48. Allen D, Lader M, Curran HV. A comparative study of the interactions of alcohol with amitriptyline, fl uoxetine and placebo in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:63-80.
49. Siepmann M, Grossmann J, Muck-Weymann M, Kirch W. Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl) 2003;168:293-8.
50. Fairweather D, Pozzo C, Kerr J, Lafferty S, Hindmarch I. Citalopram compared to dothiepin and placebo: Effects on cognitive function and psychomotor performance. Hum Psychopharmacol 1997;12:119-26. (Pubitemid 27224223)
51. Sargent P, Williamson DJ, Pearson G, Odontiadis J, Cowen PJ. Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity. Psychopharmacology (Berl) 1997;132:296-302.
52. Nemoto H, Toda H, Nakajima T, Hosokawa S, Okada Y, Yamamoto K, et al. Fluvoxamine modulates pain sensation and affective processing of pain in human brain. Neuroreport 2003;14:791-7.
53. Krieg JC, Lauer CJ, Schreiber W, Modell S, Holsboer F. Neuroendocrine, polysomnographic and psychometric observations in healthy subjects at high familial risk for affective disorders: The current state of the 'Munich vulnerability study'. J Affect Disord 2001;62:33-7.
54. Mayers AG, Van Hooff JC, Baldwin DS. Assessing subjective sleep reports in the first-degree relatives of antidepressant-treated depressed outpatients. Hum Psychopharmacol 2003;18:207-14.
55. Snitz BE, Macdonald AW, III, Carter CS. Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: A meta-analytic review of putative endophenotypes. Schizophr Bull 2006;32:179-94.
56. Chen ML. Ethnic or racial differences revisited: Impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006;45:957-64.
57. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau". Ther Drug Monit 2004;26:145-51.
58. Scordo MG, Caputi AP, D'Arrigo C, Fava G, Spina E. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 2004;50:195-200.
59. Kramer PD, Curzon G, Hughes E, Crews F. The truth about Prozac: An exchange. New York Rev Books 2008;55:54-5.
60. Knorr U, Vinberg M, Klose M, Feldt-Rasmussen U, Hilsted L, Gade A, et al. Rationale and design of the participant, investigator, observer, and data-analyst-blinded randomized AGENDA trial on associations between gene-polymorphisms, endophenotypes for depression and antidepressive intervention: The effect of escitalopram versus placebo on the combined dexamethasone-corticotrophine releasing hormone test and other potential endophenotypes in healthy firstdegree relatives of persons with depression. Trials 2009;10:66.
61. Sharpley AL, Williamson DJ, Attenburrow ME, Pearson G, Sargent P, Cowen PJ. The effects of paroxetine and nefazodone on sleep: A placebo controlled trial. Psychopharmacology (Berl) 1996;126:50-4.